Opsin Biotherapeutics, Inc.

We look forward to hearing from the 8 companies selected as 2024 Rising Stars at this year's?iC3 Life Science & Healthcare Innovation Summit?on October 3-4?at the Loews Arlington Hotel & Convention Center.? ? These featured companies were chosen for their outstanding potential to drive significant change through innovation and tenacity to address the most pressing challenges we face in healthcare and life sciences.? ? Thank you to?Dallas Innovates?for sharing more information about the 2024 Rising Stars.? ? https://lnkd.in/ePE8nqec ? Register for the Summit?https://lnkd.in/gTVMq_N2 #healthcare #pharmaceuticals #research #development #lifesciences #biotech #bioscience #biomanufacturing #biotechnology #lifescience #Texas #NorthTexas

Join BioNTX at the 10th Anniversary iC3 Life Science and Healthcare Innovation Summit on Thursday, October 3rd?– Friday, October 4th?to meet the 2024 Rising Stars — our next-generation leaders addressing the most significant challenges in healthcare and life sciences. ? These Texas-based companies are making a remarkable impact, showcasing their recent achievements and innovations. Don’t miss the chance to hear from the trailblazers shaping the future of healthcare in our community. ? Register now?https://lnkd.in/gxKSDt5b ? Read press release https://lnkd.in/dfabH83N #healthcare #research #biotechnology #bioscience #biotech #innovation #lifesciences #biomanufacturing #NorthTexas #Texas #healthcare #health #pharmaceuticals #innovators #collaboration #commercialization #capital

Join us for the ASPN Annual 5K Charity Race in Miami Beach! This exciting event is a part of the ASPN Annual Conference, offering a unique chance to enjoy the scenic beauty of Miami Beach while making a positive impact. If you're already registered for the conference, you can easily add the 5K Charity Race to your existing registration by filling out this 5K Charity Run form. https://lnkd.in/gHEjymgz Don't miss this opportunity to connect, compete, and contribute to a great cause. We look forward to seeing you there! #AnnualMeeting #ASPN2024 #PainManagement Tim Deer, MD

This is your special invite to ASPN's 6th Annual Meeting. This highly anticipated event promises to be our best yet, filled with incredible opportunities for learning, networking, and growth. ?? Date: July 11–14, 2024 ?? Location: Fontainebleau, Miami Beach Mark your calendar and register today to secure your spot: https://lnkd.in/ggpjFDaU We can’t wait to see you there! #ASPN2024 #PainManagement #Neurosurgery Reda Tolba, MD

Are you coming to Miami this July?? Get ready for an unforgettable experience at the Fontainebleau Hotel in Miami Beach. Participate in our charity 5K run for a worthy cause and rejuvenate yourself with morning Essentrics classes. And don't miss out on the Miami Heat reception—an excellent opportunity to connect with colleagues in a relaxed atmosphere. Explore the full agenda and secure your spot early. Let's build bridges together and make a difference! Register now: https://lnkd.in/ggpjFDaU #ASPNMeeting2024 #ASPN2024 #PainManagement Ashley Bailey-Classen, DO Tim Deer, MD

Yesterday in Seattle, Dr. Samarendra Mohanty made a presentation on Mutation-Agnostic Vision Restoration in Patients with Retinal Degenerative and participated in a panel discussion on regenerative medicine as part of Ophthalmology Innovation Source Retina Innovation Summit. It was a great opportunity to reconnect with colleagues and meet new people who are working in this important area of research. Today (Sunday 5/5) team Nanoscope Therapeutics Inc. takes part in the opening of #ARVO24. Stop by to meet our leadership team at our booth #4620. We look forward to saying hello as we all kick off a busy week. Monday 5/6, the first of 6 ARVO presentations featuring our MCO-010 optogenetic therapy for retinitis pigmentosa begin with one by Dr. Allen Ho where he will present 12-month results from our Phase?2b/3 RESTORE clinical trial. Details for all presentations are below and on our website: nanostherapeutics.com Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase?2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE) Presentation Number:?2137 - ?Paper Session May 6, 2024. -- 4:15 –?4:30 p.m. PT 612 -?Seattle?Convention Center - Arch Building Presenter: Allen Ho, MD, Chief Medical Advisor Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision Poster Number:?A0223 Type:?Poster Session May 7, 2024 -- 1:15 –?3:00 p.m. PT Exhibit Hall -?Seattle?Convention Center Presenter: Samuel B Barone, MD, CMO Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT) Poster Number:?B0094 May 8, 2024 -- ?2:15 –?4:00 p.m. PT Exhibit Hall -?Seattle?Convention Center Presenter: Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology, Stanford University Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa Abstract/Poster Number:?B0293 May 8, 2024 -- ?2:15 –?4:00 p.m. PT Exhibit Hall -?Seattle?Convention Center Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision Poster Number:?B0924 Session Date:?May 9, 2024 -- 8:00 –?9:45 a.m. PT Exhibit Hall -?Seattle?Convention Center Presenter: Samarendra Mohanty, PhD, President and CSO In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis Poster Number:?B0942 May 9, 2024 -- 8:00 –?9:45 a.m. PT Exhibit Hall -?Seattle?Convention Center Presenter: Naj Sharif, PhD, DSC, VP of Global Research and Development Sulagna Bhattacharya #ophthalmology #retina #clinicaltrials

Nanoscope Therapeutics Inc. management team will be at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting May 5-9 in Seattle. Connect with our team at our booth #4620 or at one of our presentations. Details for presentations are as follows: Title:?Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase?2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE) Presentation Number:?2137 Presentation Type:?Paper Session Session Title:?Retinitis Pigmentosa Session Date:?May 6, 2024 Session Time:?4:15 –?4:30 p.m. PT Location:?612 -?Seattle?Convention Center - Arch Building Presenter:?Allen Ho, MD, Chief Medical Advisor Title:?Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision Poster Number:?A0223 Type:?Poster Session Session Title:?Low Vision Performance Assessment Session Date:?May 7, 2024 Session Time:?1:15 –?3:00 p.m. PT Location:?Exhibit Hall -?Seattle?Convention Center Presenter:?Samuel B Barone, MD, CMO Title:?Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT) Poster Number:?B0094 Type:?Poster Session Session Title:?Pediatric Ophthalmology and Inherited Eye Diseases Session Date:?May 8, 2024 Session Time:?2:15 –?4:00 p.m. PT Location:?Exhibit Hall -?Seattle?Convention Center Presenter:?Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology, Stanford University Title:?Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa Abstract/Poster Number:?B0293 Type:?Poster Session Session Title:?Gene and Cell Therapies and Other Novel Therapeutics I Session Date:?May 8, 2024 Session Time:?2:15 –?4:00 p.m. PT Location:?Exhibit Hall -?Seattle?Convention Center Presenter:?Subrata Batabyal, PhD, Director, Non-Clinical Development Title:?Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision Poster Number:?B0924 Type:?Poster Session Session Title:?Gene and Cell Therapies and Other Novel Therapeutics II Session Date:?May 9, 2024 Session Time:?8:00 –?9:45 a.m. PT Location:?Exhibit Hall -?Seattle?Convention Center Presenter:?Samarendra Mohanty, PhD, President and CSO Title:?In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis Poster Number:?B0942 Type:?Poster Session Session Title:?Gene and Cell Therapies and Other Novel Therapeutics II Session Date:?May 9, 2024 Session Time:?8:00 –?9:45 a.m. PT Location:?Exhibit Hall -?Seattle?Convention Center Presenter:?Naj Sharif, PhD, DSC, VP of Global Research and Development Sulagna Bhattacharya #ophthalmology #genetherapy #biotechnology #clinicaltrials